Phase II single-arm window-of-opportunity” study of a combination of obinutuzumab (GA-101) and venetoclax (ABT-199) in relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

AGMT gGmbH0 个研究点目标入组 21 人开始时间: 2016年9月16日最近更新: 2021年11月29日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方
入组人数: 21

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•- Patients = 18 years of age
•- Ability and willingness to comply with the study protocol procedures.
•- Diffuse large B-cell lymphoma (DLBCL)
•o with histologically confirmed relapse within 12 months after having achieved a PR or CR with initial R-anthracycline containing therapy, or
•o with refractoriness to initial R-anthracycline containing therapy (not achieving at least a partial response)
•o Bcl-2 protein expression detected by immunohistochemistry.
•- Adequate organ function, defined as the following:
•o Total bilirubin must be < 1.5 x the upper limit of the normal (ULN) unless the elevation is known to be due to Gilbert syndrome.
•o ALT and AST must be = 3 x the upper limit of the normal range. AST and ALT may be elevated up to 5 times the ULN if their elevation can be reasonably ascribed to the presence of lymphoma in the liver. Serum creatinine must be < 2.0 mg/dL and/or creatinine clearance or calculated creatinine clearance = 50 mL/minute.
•- Signed Informed Consent Form(s).
•- At least one bi-dimensionally measurable lesion on CT scan defined as > 1.5 cm in its longest dimension.
•- Confirmed availability of archival or freshly biopsied tumor tissue meeting protocol-defined-specifications prior to study enrolment.
•- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2.
•- Adequate hematologic function (unless caused by underlying disease, as established by extensive bone marrow involvement or as a result of hypersplenism secondary to the involvement of the spleen by lymphoma per the investigator) defined as follows:
•o Hemoglobin = 9 g/dL
•o Absolute neutrophil count = 1.5 × 109/L and
•o Platelet count = 75 × 109/L.
•- For women who are not postmenopausal (= 12 months of non-therapy-induced amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to remain abstinent or use single or combined non-hormonal contraceptive methods that result in a failure rate of < 1% per year during the treatment period and for at least 18 months after the last dose of obinutuzumab. Abstinence is only acceptable if it is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception. Examples of non-hormonal contraceptive methods with a failure rate of < 1% per year include tubal ligation, male sterilization, and certain intrauterinedevices. Alternatively, two methods (e.g., two barrier methods such as a condom and a cervical cap) may be combined to achieve a failure rate of < 1% per year. Barrier methods must always be supplemented with the use of a spermicide.
•- Non-vasectomized male patients must practice at least one of the following methods of birth control throughout the duration of study participation and for at least 12 months after completing therapy with obinutuzumab. A partner who is surgically sterile or postmenopausal (for at least 1 year) or who is taking hormonal contraceptives (oral, parenteral, vaginal ring, ortransdermal) for at least 3 months prior to study drug administration. Total abstinence from sexual intercourse; double-barrier method (condom + diaphragm or cervical cup with spermicidal, contraceptive sponge, jellies, or cream). Abstinence is only acceptable if it is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal,

排除标准

•Patient has received any other investigational treatment within 28 days before study entry.
•Known hypersensitivity to recombinant proteins, murine proteins, or to any excipient contained in the drug formulation of obinutuzumab or venetoclax.
•DLBCL transformed from other malignancies or CD20 negative DLBCL.
•Radiation, chemotherapy, or immunotherapy or any other anticancer therapy = 4 weeks prior to Cycle 1 Day 1.
•Ongoing corticosteroid use > 30 mg/day of prednisone or equivalent. Patients who received corticosteroid treatment with = 30 mg/day of prednisone or equivalent must be documented to be on a stable dose of at least 4 weeks duration prior to randomization (Cycle 1 Day 1). Patients may have received a brief (< 7 days) course of systemic steroids (= 100 mg prednisone equivalent) prior to initiation of study therapy for control of lymphoma-related symptoms.
•ECOG performance status = 3.
•Female patients who are pregnant or breast-feeding.
•Acute or uncontrolled chronic infections.
•Known diagnosis of HIV (HIV testing is not required as part of this study).
•Any serious medical or psychiatric illness that could, in the investigator’s opinion, potentially interfere with the completion of treatment according to the protocol.
•Known cerebral or meningeal disease, including signs or symptoms of PML.
•Symptomatic neurologic disease compromising normal activities of daily living or requiring medications.
•Any sensory or motor peripheral neuropathy greater than or equal to Grade 2.
•Known history of any of the following cardiovascular conditions:
•o myocardial infarction within 2 years of study entry,
•o NYHA Class III or IV heart failure,
•o evidence of current uncontrolled cardiovascular conditions, including cardiac arrhythmias, congestive heart failure, angina, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities,
•o recent evidence (within 6 months before first dose of study drug) of a left-ventricular ejection fraction <50% .
•Diagnosed or treated for another malignancy within 3 years before the first dose or previously diagnosed with another malignancy and have evidence of residual disease.
•Patients with transformed lymphoma.
•Primary CNS lymphoma.
•Vaccination with live vaccines within 28 days prior to treatment.
•History of other malignancy that could affect compliance with the protocol or interpretation of results (Patients with a history of curatively treated basal or squamous cell carcinoma or Stage 1 melanoma of the skin or in situ carcinoma of the cervix are eligible).
•Patients with a malignancy that has been treated with surgery alone with curative intent will also be excluded, unless the malignancy has been in documented remission without treatment for = 3 years prior to enrollment.
•Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results or that could increase risk to the patient.
•Significant pulmonary disease
•Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection at study enrollment, or any major episode of infection requiring treatment with IV antibiotics or hospitalization (relating to the completion of the course of antibiotics) within 4 weeks prior to Cycle 1 Day 1.
•Requires the use of warfarin (because of potential drug-drug interactions that may potentially increase the exposure of warfarin).
•Received the following agents within 7 days prior to the first dose of venetoclax:

研究者

发起方

AGMT gGmbH

相似试验

尚未招募

2 期

Addition of resveratrol copper with chemotherapy in gastric cancer patients

CTRI/2019/07/020289Tata Memorial Hospital

进行中（未招募）

1 期

A clinical study to assess the cobination of two drugs (177Lu-DOTATATE and nivolumab) in neuroendocrine tumourseuroendocrine neoplasms (Grade 3 well-differentiated neuroendocrine tumours (NET) or poorly differentiated neuroendocrine carcinomas (NEC))MedDRA version: 20.0 Level: PT Classification code 10057270 Term: Neuroendocrine carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0 Level: PT Classification code 10052399 Term: Neuroendocrine tumour System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0 Level: LLT Classification code 10062476 Term: Neuroendocrine tumor System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2019-002974-29-ESFundación de investigación de HM Hospitales30

尚未招募

2 期

Dose-Dense ABVD Study: An accelerated delivery of Adriamycin, Bleomycin, Vinblastin and Dacarbazine for patients with Hodgkin LymphomaEarly Stage Unfavourable Hodgkin LymphomaAdvanced Stage Hodgkin LymphomaCancer - Hodgkin's

ACTRN12612000137897Queensland Health31

终止

2 期

A single arm, prospective Phase II study of Split-Course PelvicRadiotherapy for Locally Progressive, Castrate Resistant Prostate CancerCastrate Resistant Prostate CancerCancer - Prostate

ACTRN12614000858695Radiation Oncology Services - Mater Centre18

进行中（未招募）

1 期

A clinical trial to look at the safety and possible benefit of using the new drug AZD4547 together with anastrozole or letrozole (drugs belonging to the group non-steroidal aromatase inhibitors” in oestrogen receptor positive (ER positive)breast cancer patients who have progressed on treatment with anastrozole or letrozoleER Positive Progressing Breast CancerMedDRA version: 19.0 Level: SOC Classification code 10029104 Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps) System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2011-000454-32-GBImperial College London56